{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.4","upperLimit":"10.3","value":"5.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"IRC assessed duration of clinical benefit per 2016 IMWG criteria: Duration from first response (at least MR) to time of IRC-determined PD or death due to disease progression, whichever occurs first. Minimal response (MR): \\>= 25% but \\< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \\>= 0.5 g/dL; Serum M-protein increase \\>= 1 g/dL if the lowest M-component was \\>=5 g/dL; Urinary M-protein (absolute increase must be \\>= 200 mg per 24 hours). Analysis was performed using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with quad-exposed, double-class-refractory (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, but not an anti-CD38 mab) and penta-exposed, triple-class-refractory MM (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an IMiD, a PI, and the anti-CD38 mAb daratumumab) received, two dosing schedules (1) selinexor 80 mg plus low-dose dexamethasone 20 mg (Sd) twice-weekly on Days 1 and 3 for 3 weeks of each 4-week cycle (2) selinexor 80 mg plus low-dose dexamethasone 20 mg (Sd) twice-weekly continuously in 4-week cycles; until disease progression, death, or unacceptable toxicity (maximum duration of approximately 13 months).","id":"OG000","title":"Part 1"}],"paramType":"MEDIAN","populationDescription":"Safety population consisted of all participants, who had received at least 1 dose of study treatment (partial or complete) and had any post-baseline safety information. Here, \"Overall number of participants analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"First response subsequently confirmed to disease progression, or death, whichever occurred first (maximum duration of 13 months)","title":"Part 1: Duration of Clinical Benefit Per IMWG as Assessed by IRC","type":"SECONDARY","unitOfMeasure":"Months"}